Patents by Inventor Scott Martin GLASER

Scott Martin GLASER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CCR7 antibody drug conjugates
    Patent number: 12180291
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: December 31, 2024
    Assignee: NOVARTIS AG
    Inventors: Steven Bender, Tracy Charlton, Anna Galkin, Bernhard Hubert Geierstanger, Scott Martin Glaser, Shailaja Kasibhatla, Mark Knuth, Sabine Rottmann, Sarah Rue, Glen Spraggon, Tetsuo Uno
  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20240336701
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: January 30, 2024
    Publication date: October 10, 2024
    Inventors: Michael DIDONATO, Christoph ERKEL, Anna Galkin, Scott Martin GLASER, Klaus Felix HARTLEPP, Yong JIA, Alexandra KRAUS, Christian Cho-Hua LEE, Sarah Michelle RUE, Jian SHI, Xenia Karola WEZLER
  • ANTI-CCR7 ANTIBODY DRUG CONJUGATES
    Publication number: 20240092918
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: February 3, 2023
    Publication date: March 21, 2024
    Inventors: Steven BENDER, Tracy CHARLTON, Anna GALKIN, Bernhard Hubert GEIERSTANGER, Scott Martin GLASER, Shailaja KASIBHATLA, Mark KNUTH, Sabine ROTTMANN, Sarah RUE, Glen SPRAGGON, Tetsuo UNO
  • Anti-CCR7 antibody drug conjugates
    Patent number: 11634497
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: April 25, 2023
    Assignee: NOVARTIS AG
    Inventors: Steven Bender, Tracy Charlton, Anna Galkin, Bernhard Hubert Geierstanger, Scott Martin Glaser, Shailaja Kasibhatla, Mark Knuth, Sabine Rottmann, Sarah Rue, Glen Spraggon, Tetsuo Uno
  • DC-SIGN ANTIBODY DRUG CONJUGATES
    Publication number: 20230053449
    Abstract: Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 23, 2023
    Inventors: Lisa BARNETT, Steven BENDER, Alex Cortez, Sarah COX, Jonathan DEANE, Scott Martin GLASER, Ben WEN, Tom Yao-Hsiang WU
  • ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
    Publication number: 20220348651
    Abstract: Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.
    Type: Application
    Filed: September 17, 2020
    Publication date: November 3, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES
    Publication number: 20220340685
    Abstract: Provided herein are combinations comprising an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to ENTPD2 (e.g., human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to CD73 (e.g., human CD73 protein), and methods of using these combinations.
    Type: Application
    Filed: September 17, 2020
    Publication date: October 27, 2022
    Inventors: Michael DiDonato, Mirek Dostalek, Christoph Erkel, Javier Estrada Diez, Anna Galkin, Scott Martin Glaser, Klaus Felix Hartlepp, Yong Jia, Deborah A. Knee, Alexandra Kraus, Christian Cho-Hua Lee, Luigi Manenti, Sarah Michelle Rue, Jian Shi, Xenia Karola Wezler, Gabrielle Wong
  • DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS
    Publication number: 20210170043
    Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.
    Type: Application
    Filed: October 30, 2019
    Publication date: June 10, 2021
    Inventors: Lisa BARNETT, Steven BENDER, Charles Y. CHO, Sarah COX, Jonathan Deane, Scott Martin GLASER, Xueshi Hao, Shailaja KASIBHATLA, Weijia OU, Tetsuo UNO, Yongqin WAN, Ben WEN, Tom Yao-Hsiang WU
  • ANTI-CCR7 ANTIBODY DRUG CONJUGATES
    Publication number: 20200216548
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: February 1, 2018
    Publication date: July 9, 2020
    Inventors: Steven BENDER, Tracy CHARLTON, Anna GALKIN, Bernhard Hubert GEIERSTANGER, Scott Martin GLASER, Shailaja KASIBHATLA, Mark KNUTH, Sabine ROTTMANN, Sarah RUE, Glen SPRAGGON, Tetsuo UNO